- Home
- ZLAB vs SIGA Comparison
ZLAB vs SIGA Comparison
Compare ZLAB & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- SIGA
- Stock Information
- Founded
- ZLAB 2013
- SIGA 1995
- Country
- ZLAB China
- SIGA United States
- Employees
- ZLAB N/A
- SIGA N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- ZLAB Health Care
- SIGA Health Care
- Exchange
- ZLAB Nasdaq
- SIGA Nasdaq
- Market Cap
- ZLAB 3.6B
- SIGA 422.9M
- IPO Year
- ZLAB 2017
- SIGA 1997
- Fundamental
- Price
- ZLAB $34.33
- SIGA $6.85
- Analyst Decision
- ZLAB Buy
- SIGA
- Analyst Count
- ZLAB 5
- SIGA 0
- Target Price
- ZLAB $54.28
- SIGA N/A
- AVG Volume (30 Days)
- ZLAB 782.4K
- SIGA 388.3K
- Earning Date
- ZLAB 08-05-2025
- SIGA 07-31-2025
- Dividend Yield
- ZLAB N/A
- SIGA 8.86%
- EPS Growth
- ZLAB N/A
- SIGA N/A
- EPS
- ZLAB N/A
- SIGA 0.67
- Revenue
- ZLAB $418,326,000.00
- SIGA $120,330,310.00
- Revenue This Year
- ZLAB $44.07
- SIGA N/A
- Revenue Next Year
- ZLAB $49.13
- SIGA $95.31
- P/E Ratio
- ZLAB N/A
- SIGA $10.09
- Revenue Growth
- ZLAB 43.72
- SIGA N/A
- 52 Week Low
- ZLAB $16.01
- SIGA $4.95
- 52 Week High
- ZLAB $44.34
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- ZLAB 45.43
- SIGA 63.76
- Support Level
- ZLAB $32.31
- SIGA $6.70
- Resistance Level
- ZLAB $35.72
- SIGA $7.07
- Average True Range (ATR)
- ZLAB 1.08
- SIGA 0.21
- MACD
- ZLAB -0.49
- SIGA 0.02
- Stochastic Oscillator
- ZLAB 27.49
- SIGA 75.29
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.